Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hybutimibe (Hanhui Pharmaceutical)
- Development stage
- Phase 4
- Lead developer
- Hanhui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Hybutimibe is a pharmaceutical drug classified as a cardiovascular therapy. It functions as an inhibitor of the Niemann-Pick C1-Like 1 (NPC1L1) protein, which plays a crucial role in cholesterol absorption. This mechanism of action makes Hybutimibe effective in the treatment of hypercholesterolemia. It has received its first global approval in China for both monotherapy and combination therapy for hypercholesterolemia.
02
Targets
NPC1L1 (Niemann-pick C1-Like 1 transporter)
Beyond the preview
Go deeper on Hybutimibe (Hanhui Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hybutimibe (Hanhui Pharmaceutical).